EGFR and breast cancer: Clinical data suggest that breast cancer patients with tumors overexpressing HER2/neu, a member of ErbB family of receptor tyrosine kinases (RTKs), live one-third shorter than the patients with a HER-2/neu negative tumor, and the enhancement of HER2 copies is also correlated with the relapsing time of the disease (Arteaga et al. 2012; Asada et al. 2002; Slamon et al. 1987).